Cargando…
Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545690/ https://www.ncbi.nlm.nih.gov/pubmed/34492123 http://dx.doi.org/10.1111/all.15083 |
| _version_ | 1784804875778916352 |
|---|---|
| author | Bégin, Philippe Bird, John Andrew Spergel, Jonathan M. Campbell, Dianne E. Green, Todd D. Bee, Katharine J. Lambert, Romain Sampson, Hugh A. Fleischer, David M. |
| author_facet | Bégin, Philippe Bird, John Andrew Spergel, Jonathan M. Campbell, Dianne E. Green, Todd D. Bee, Katharine J. Lambert, Romain Sampson, Hugh A. Fleischer, David M. |
| author_sort | Bégin, Philippe |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9545690 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95456902022-10-14 Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy Bégin, Philippe Bird, John Andrew Spergel, Jonathan M. Campbell, Dianne E. Green, Todd D. Bee, Katharine J. Lambert, Romain Sampson, Hugh A. Fleischer, David M. Allergy Letters John Wiley and Sons Inc. 2021-09-28 2021-12 /pmc/articles/PMC9545690/ /pubmed/34492123 http://dx.doi.org/10.1111/all.15083 Text en Allergy© 2022 DBV Technologies. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Letters Bégin, Philippe Bird, John Andrew Spergel, Jonathan M. Campbell, Dianne E. Green, Todd D. Bee, Katharine J. Lambert, Romain Sampson, Hugh A. Fleischer, David M. Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| title | Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| title_full | Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| title_fullStr | Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| title_full_unstemmed | Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| title_short | Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| title_sort | reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy |
| topic | Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545690/ https://www.ncbi.nlm.nih.gov/pubmed/34492123 http://dx.doi.org/10.1111/all.15083 |
| work_keys_str_mv | AT beginphilippe reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT birdjohnandrew reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT spergeljonathanm reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT campbelldiannee reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT greentoddd reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT beekatharinej reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT lambertromain reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT sampsonhugha reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy AT fleischerdavidm reductioninpeanutreactionseverityduringoralchallengeafter12monthsofepicutaneousimmunotherapy |